 |
Results of First-In-Man Study With MIVT Low Dose Polymer-Free Drug-Eluting Stent to Be Presented at TCT Conference (Marketwire via Yahoo! Finance) |
MIV Therapeutics, Inc. (Frankfurt: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that results of the first-in-man safety study with the Company’s drug-eluting stent will be presented at the Transcatheter Cardiovascular Therapeutics 2007 conference, to be held October 20-25 at …
More: continued here
This entry was posted on Wednesday, October 17th, 2007 and is filed under POLYMER. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Leave a comment